share_log

UBS Downgrades Cano Health to Sell, Lowers Price Target to $3.75

Benzinga ·  Nov 17, 2023 23:48

UBS analyst Andrew Mok downgrades Cano Health (NYSE:CANO) from Neutral to Sell and lowers the price target from $12 to $3.75.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment